Innovate UK awards Atlas Genetics £2m SBRI phase II Contract
14 August 2017
Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded a two year Innovate UK phase II contract to expand the Sexually Transmitted Infection (STI) test menu for the io® rapid diagnostic platform and support its adoption into UK sexual health clinics.
Dealmaking in 2017: Striking a Balance
14 August 2017
inVentiv Health Consulting’s Neel Patel tells Pharm Exec that biopharma dealmaking in 2017 is robust and generally immune to external pressures in the short term—but the art of the deal is still being compromised by factors under the buyer and seller’s control.
Stanford University and Takeda will collaborate on drug discovery
14 August 2017
A new partnership between Stanford University and one of the world’s oldest and largest drug makers, Takeda Pharmaceutical Company Ltd., could help speed up the process of bringing drugs from discovery to market.
Teva has long-term plans for the Russian market
11 August 2017
In its financial report for Q2 2017, Teva announced that it was curtailing the activities in 45 countries. The Russian office continues to operate as usual, without any changes in its operating activities. The company is successfully developing the local manufacturing at its plant in Yaroslavl and has long-term plans for the Russian market, which remains a strategic one for Teva.
10 August 2017
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended June 30, 2017 . In addition, the Company provided a clinical and business update. As of June 30, 2017 , Syndax had $130.0 million in cash, cash equivalents and short-term investments.
What do kids think of their parents' RA? Amgen's new Enbrel push offers a few ideas
10 August 2017
In Amgen’s latest campaign for Enbrel, kids are speaking up. Two new TV commercials feature children talking about their parents’ painful arthritis and their worries about it. The “Being There” campaign includes one TV ad focused on a mother, and another on a father. The TV ads began running last week, backed by combined spending of just under $2 million so far, according to data from real-time TV tracker iSpot.tv.
Pfizer commits $100M for a gene therapies plant in North Carolina
10 August 2017
Pfizer committed to building a $100 million gene therapies plant in North Carolina and in exchange, North Carolina committed to providing the drugmaker with a quarter-million dollars' worth of help.
09 August 2017
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter and six months ended June 30, 2017 and provided an update on its development programs.
Pfizer will invest $100 million into gene therapy development
09 August 2017
Pharmaceutical giant Pfizer Inc. plans to invest $100 million in its US Sanford operations as part of a push into gene therapy, officials said. The effort builds on a technology developed at the University of North Carolina at Chapel Hill and will create 40 jobs in Sanford. Preliminary work on the expansion and initial hiring have already begun. The 230-acre campus employs about 450 people.
Clearside Biomedical, Inc. Announces Changes to its Board of Directors
08 August 2017
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that George Lasezkay, Pharm.D., J.D. has been appointed to its board of directors, effective immediately. Dr. Lasezkay will succeed Derek Yoon, who resigned from the board as of August 8, 2017.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024